title: Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.
abstract: Endothelin-1 (ET-1) is a potent mitogen and modulator of vascular tone. It is synthesized and released from endothelial cells and acts upon two receptor subtypes designated as ETA and ETB. In this study, a series of potent dipeptide sulfonamide dual-endothelin ETA/ETB receptor antagonists were prepared to investigate their potential benefit in vascular diseases. CGS 31398 inhibited [125I]ET-1 binding to human ETA and ETB receptors expressed in Chinese hamster ovary (CHO) cells (ETA/CHO, ETB/CHO) with respective IC50 values of 0.26 and 0.12 nM. However, in anesthetized rats, this compound markedly potentiated ET-1-induced renal vascular resistance, a response normally observed with selective ETB receptor antagonists. To determine whether species differences account for these results, a direct comparison was made between binding to rat and rabbit aortic membranes versus functional antagonism in isolated rat aortic rings. It was found that CGS 31398 had potent affinity for the ETA receptor in rat and rabbit aorta with IC50 values of 0.87 and 0.79 nM, respectively. Inhibition of ET-1-induced contractions of rat aorta by the compound was considerably weaker than expected (pKB = 6.4), while that of sarafotoxin S6c induced contraction of dog saphenous vein (100% inhibition at 100 nM) was consistent with corresponding binding data. These results suggest that although CGS 31398 is a potent dual inhibitor of ETA/ETB receptor binding, it surprisingly displays potent ETB and weak ETA receptor antagonism in functional assays.
authors.affiliation: Metabolic and Cardiovascular Diseases Research, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA. gary.ksander@pharma.novartis.com
authors.forename: Gary M
authors.initials: GM
authors.lastname: Ksander
authors.forename: Suraj S
authors.initials: SS
authors.lastname: Shetty
authors.forename: Dominick
authors.initials: D
authors.lastname: DelGrande
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Balwierczak
authors.forename: Charles W
authors.initials: CW
authors.lastname: Bruseo
authors.forename: Paula
authors.initials: P
authors.lastname: Savage
authors.forename: Reynalda
authors.initials: R
authors.lastname: deJesus
authors.forename: Andrew
authors.initials: A
authors.lastname: Yuan
authors.forename: Randy L
authors.initials: RL
authors.lastname: Webb
authors.forename: Arco Y
authors.initials: AY
authors.lastname: Jeng
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism; D016466:CHO Cells; D006224:Cricetinae; D004151:Dipeptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D065128:Endothelin Receptor Antagonists; D006801:Humans; D008297:Male; D009924:Organ Culture Techniques; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000378:metabolism; D013449:Sulfonamides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology
chemical_list: D004151:Dipeptides; D065128:Endothelin Receptor Antagonists; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D013449:Sulfonamides